11 May 2023
Latham & Watkins Advises Sobi in Acquisition of CTI BioPharma Corp.
Advising firms
Deal team
35 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Scott Shean Lead | Latham & Watkins LLP | Partner | corporate | Orange County |
| Leah Sauter Lead | Latham & Watkins LLP | Partner | corporate | New York |
| Jennifer Wong | Latham & Watkins LLP | Associate | corporate | New York |
| Ozden Samur-LaBruna | Latham & Watkins LLP | Associate | corporate | New York |
| Emma Green | Latham & Watkins LLP | Associate | corporate | New York |
| Elizabeth Richards | Latham & Watkins LLP | Partner | healthcare and FDA regulatory | Washington, D.C. |
| Christopher Schott | Latham & Watkins LLP | Partner | healthcare and FDA regulatory | Washington, D.C. |
| Eveline Van Keymeulen | Latham & Watkins LLP | Partner | healthcare and FDA regulatory | Paris |
| Nicole Liffrig Molife | Latham & Watkins LLP | Counsel | healthcare and FDA regulatory | Washington, D.C. |
| Kathryn Culver | Latham & Watkins LLP | Associate | healthcare and FDA regulatory | Washington, D.C. |
| Margaret Rote | Latham & Watkins LLP | Associate | healthcare and FDA regulatory | Washington, D.C. |
| Daniel Machado | Latham & Watkins LLP | Associate | healthcare and FDA regulatory | Washington, D.C. |
| Maria Malas | Latham & Watkins LLP | Associate | healthcare and FDA regulatory | Washington, D.C. |
| Jeanne Fabre | Latham & Watkins LLP | Associate | healthcare and FDA regulatory | Paris |
| Steven Chinowsky | Latham & Watkins LLP | Partner | intellectual property | San Diego |
| Darryl Steensma | Latham & Watkins LLP | Counsel | intellectual property | Not stated |
| Michelle Gross | Latham & Watkins LLP | Partner | data privacy | Bay Area |
| Adriana Beach | Latham & Watkins LLP | Associate | data privacy | Not stated |
| Grace Lee | Latham & Watkins LLP | Partner | tax | Bay Area |
| Kirt Switzer | Latham & Watkins LLP | Partner | tax | Bay Area |
| Alexander Farris | Latham & Watkins LLP | Associate | tax | Not stated |
| Rasha Suleiman | Latham & Watkins LLP | Associate | tax | Not stated |
| Michelle Carpenter | Latham & Watkins LLP | Partner | employment, benefits and compensation | Los Angeles |
| Sara Schlau | Latham & Watkins LLP | Associate | employment, benefits and compensation | Not stated |
| Viva Jerónimo | Latham & Watkins LLP | Associate | employment, benefits and compensation | Not stated |
| Joshua Holian | Latham & Watkins LLP | Partner | antitrust | Bay Area |
| Héctor Armengod | Latham & Watkins LLP | Partner | antitrust | Brussels |
| Patrick English | Latham & Watkins LLP | Counsel | antitrust | Washington, D.C. |
| Erin Brown Jones | Latham & Watkins LLP | Partner | sanctions and anticorruption | Washington, D.C. |
| Andrew Galdes | Latham & Watkins LLP | Counsel | sanctions and anticorruption | Not stated |
| Allison Hugi | Latham & Watkins LLP | Associate | sanctions and anticorruption | Not stated |
| Nathan Whitaker | Latham & Watkins LLP | Partner | finance | Los Angeles |
| Jonathan Shih | Latham & Watkins LLP | Counsel | finance | Not stated |
| Julia Steinberg | Latham & Watkins LLP | Associate | finance | Not stated |
| David Califano | Latham & Watkins LLP | Associate | securities | New York |
Stated terms
- Stated value
- USD 1.70bn (US$1.7 billion)
- What the figure measures
- Total transaction value
- Client
- Swedish Orphan Biovitrum AB (publ) (Sobi)Buy-side
- Counterparties
- CTI BioPharma Corp. (Sell-side)